Site Search

Search market news

Find public news by keyword, exact ticker, category and date.

News by ticker →AAPL news SPY news Earnings

News Feed

4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.

News 2026-09-24 10:05 UTC

BRIEF — Medicinova Announces Completion Of Last Patient, Last Visit In The Double — Blind Portion Of The Phase 2B/3 Combat — Als Trial Of Mn — 166

Sept 24 (Reuters) — MediciNova Inc: Medicinova Announces Completion Of Last Patient, Last Visit In The Double-blind Portion Of The Phase 2b/3 Combat-als Trial Of Mn-166 (Ibudilast) Medicinova - Topline Results From Double-blind Portion Expected By End Of 2026 Source text:... Further company coverage: MNOV.O (Reuters.Br

MNOV.O

News 2026-09-24 10:04 UTC

MNOV Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) Topline data by EOY

News 2026-09-24 10:01 UTC

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the dou…

MNOV

News 2026-09-24 10:00 UTC

MNOV - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)